drugset / Trial / NCT05968430

Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

NCT05968430

Phase 3 Active not recruiting 1076 enrolled Mineralys Therapeutics Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypertension

Timeline

Start
2023-07-14
Primary completion
2025-12-30
Completion
2027-05

Drugs

EvaluationDrugModalityDoseRoute
Subject lorundrostat Small molecule Oral

Indications